tipifarnib has been researched along with s-trans,trans-farnesylthiosalicylic acid in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (s-trans,trans-farnesylthiosalicylic acid) | Trials (s-trans,trans-farnesylthiosalicylic acid) | Recent Studies (post-2010) (s-trans,trans-farnesylthiosalicylic acid) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 174 | 5 | 86 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Korzeniecki, C; Priefer, R | 1 |
1 review(s) available for tipifarnib and s-trans,trans-farnesylthiosalicylic acid
| Article | Year |
|---|---|
Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
Topics: Humans; Models, Molecular; Molecular Structure; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2021 |